Aptevo Therapeutics Stock Performance

APVO Stock  USD 6.60  0.59  9.82%   
The firm shows a Beta (market volatility) of 0.81, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aptevo Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aptevo Therapeutics is expected to be smaller as well. At this point, Aptevo Therapeutics has a negative expected return of -2.29%. Please make sure to confirm Aptevo Therapeutics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Aptevo Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Aptevo Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more

Actual Historical Performance (%)

One Day Return
(6.24)
Five Day Return
(18.23)
Year To Date Return
(36.00)
Ten Year Return
(100.00)
All Time Return
(100.00)
Last Split Factor
1:18
Dividend Date
2020-03-27
Last Split Date
2025-12-30
1
Is Aptevo Therapeutics Inc. stock bottoming out - 2025 Earnings Impact Momentum Based Trading Ideas - newser.com
11/17/2025
2
Aptevo Therapeutics May Find a Bottom Soon, Heres Why You Should Buy the Stock Now
11/19/2025
3
Volume Report Is Aptevo Therapeutics Inc stock supported by strong fundamentals - Share Buyback Accurate Intraday Trading Signals - moha.gov.vn
12/11/2025
4
Aptevo Therapeutics announces 1-for-18 reverse stock split
12/26/2025
5
Will Aptevo Therapeutics Inc. stock continue upward momentum - July 2025 Highlights Low Risk Growth Stock Ideas - ulpravda.ru
01/08/2026
6
Aptevo Therapeutics Secures 60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
01/09/2026
7
Aptevo Therapeutics Inc. Short Interest Update
01/13/2026
8
Aptevo Therapeutics Announces Offering of 7.075 Million S - GuruFocus
01/28/2026
9
Disposition of 158 shares by Daphne Taylor of Aptevo Therapeutics subject to Rule 16b-3
02/02/2026
10
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
02/03/2026

Aptevo Therapeutics Relative Risk vs. Return Landscape

If you would invest  2,808  in Aptevo Therapeutics on November 8, 2025 and sell it today you would lose (2,207) from holding Aptevo Therapeutics or give up 78.6% of portfolio value over 90 days. Aptevo Therapeutics is currently does not generate positive expected returns and assumes 6.6864% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Aptevo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Aptevo Therapeutics is expected to under-perform the market. In addition to that, the company is 8.74 times more volatile than its market benchmark. It trades about -0.34 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

Aptevo Therapeutics Target Price Odds to finish over Current Price

The tendency of Aptevo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 6.60 90 days 6.60 
about 91.36
Based on a normal probability distribution, the odds of Aptevo Therapeutics to move above the current price in 90 days from now is about 91.36 (This Aptevo Therapeutics probability density function shows the probability of Aptevo Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Aptevo Therapeutics has a beta of 0.81. This suggests as returns on the market go up, Aptevo Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Aptevo Therapeutics will be expected to be much smaller as well. Additionally Aptevo Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Aptevo Therapeutics Price Density   
       Price  

Predictive Modules for Aptevo Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aptevo Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aptevo Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.107.7914.48
Details
Intrinsic
Valuation
LowRealHigh
5.9499.38106.07
Details
Naive
Forecast
LowNextHigh
0.042.068.75
Details
1 Analysts
Consensus
LowTargetHigh
343.98378.00419.58
Details

Aptevo Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Aptevo Therapeutics is not an exception. The market had few large corrections towards the Aptevo Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aptevo Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aptevo Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-2.1
β
Beta against Dow Jones0.81
σ
Overall volatility
7.54
Ir
Information ratio -0.32

Aptevo Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aptevo Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aptevo Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Aptevo Therapeutics generated a negative expected return over the last 90 days
Aptevo Therapeutics has high historical volatility and very poor performance
Aptevo Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (24.13 M) with profit before overhead, payroll, taxes, and interest of 345 K.
Aptevo Therapeutics currently holds about 29.43 M in cash with (23.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78.
Aptevo Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Aptevo Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aptevo Stock often depends not only on the future outlook of the current and potential Aptevo Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aptevo Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding767.05
Cash And Short Term Investments8.7 M

Aptevo Therapeutics Fundamentals Growth

Aptevo Stock prices reflect investors' perceptions of the future prospects and financial health of Aptevo Therapeutics, and Aptevo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aptevo Stock performance.

About Aptevo Therapeutics Performance

By examining Aptevo Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Aptevo Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Aptevo Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 902.31  947.42 
Return On Tangible Assets(1.39)(1.32)
Return On Capital Employed(3.01)(2.86)
Return On Assets(1.78)(1.69)
Return On Equity(5.84)(6.13)

Things to note about Aptevo Therapeutics performance evaluation

Checking the ongoing alerts about Aptevo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aptevo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Aptevo Therapeutics generated a negative expected return over the last 90 days
Aptevo Therapeutics has high historical volatility and very poor performance
Aptevo Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (24.13 M) with profit before overhead, payroll, taxes, and interest of 345 K.
Aptevo Therapeutics currently holds about 29.43 M in cash with (23.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78.
Aptevo Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Evaluating Aptevo Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Aptevo Therapeutics' stock performance include:
  • Analyzing Aptevo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aptevo Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Aptevo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Aptevo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aptevo Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Aptevo Therapeutics' stock. These opinions can provide insight into Aptevo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Aptevo Therapeutics' stock performance is not an exact science, and many factors can impact Aptevo Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Will Biotechnology sector continue expanding? Could Aptevo diversify its offerings? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptevo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
7.4 K
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.79)
Return On Equity
(2.43)
Understanding Aptevo Therapeutics requires distinguishing between market price and book value, where the latter reflects Aptevo's accounting equity. The concept of intrinsic value - what Aptevo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aptevo Therapeutics' price substantially above or below its fundamental value.
Understanding that Aptevo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptevo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aptevo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.